Australian Pharma Warns Against Removing Orphan Fee Incentives
This article was originally published in PharmAsia News
Executive Summary
Australia's pharmaceutical industry association, Medicines Australia, has objected to proposals by the Therapeutic Goods Administration to eliminate fee waivers for the registration and evaluation of orphan drugs. The association warns that if this incentive is removed, "local sponsors may not invest in bringing these products to market in Australia as this would not be commercially viable in many instances".
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.